Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality. More effective treatment approaches are needed. Traditionally, whole-brain radiotherapy has been used for palliation. With advances in radiation oncology, stereotactic radiosurgery and hypofractionated stereotactic radiotherapy have been utilized for RCC brain metastases, producing excellent outcomes. This review details the role of radiotherapy in various subgroups of patients with RCC brain metastases as well as the associated toxicities and outcomes. Newer radiosensitizers (eg, motexafin gadolinium [Xcytrin]) and chemotherapeutic agents (eg, temozolomide [Temodar]) used in combination with radiotherapy will also be discussed.
The incidence of renal cell carcinoma (RCC) has increased for more than 2 decades. The cause of the increase is not known, but improved diagnostic techniques and early detection are suspected to be contributors. According to the US census and cancer statistics, carcinoma of the kidneys affected approximately 36,160 lives in 2005,[2,3] more than 80% of whom had RCC. A third of the patients with RCC have evidence of metastases at the time of the diagnosis, and up to half of the patients treated for localized disease eventually develop a recurrence. Approximately 4% to 17% of all RCC patients eventually develop brain metastases, with 50% of these suffering from multiple lesions. Untreated, patients with brain metastasis from RCC have a poor prognosis and a mean survival of 3.2 months. The distribution of RCC brain metastases, as with many other types of brain metastases, parallels brain weight and blood flow.
RCC is considered to be radioresistant. Conventional radiation therapy has not been effective in controlling this type of tumor in the curative or adjuvant settings. The lack of effectiveness may well be due to the intrinsic radioresistance of the tumor. In the linear-quadratic model, a low alpha-beta ratio implies radioresistance. Recent experiments with human cell lines of RCC have revealed a low alpha-beta ratio, ranging from 2.6 to 6.92. (Table 1).[8-10] The exact cellular mechanisms of radioresistance in RCC remain elusive, but various intranuclear and extranuclear molecular markers (including p53, BRCA1, BRCA2, HER2/neu, Bcl-2, PI-3k, ataxia telangiectasia kinase, IFG-I, HER1, HER2, VEGF, and ECF) have been shown to influence radiosensitivity for other tumor types.
On the other hand, the failure of radiation to control RCC in the curative or adjuvant setting may have more to do with the tolerance of neighboring structures to the kidney than intrinsic tumor resistance. The organs of the abdomen including the liver and small bowel have a relatively low tolerance for radiation, and thus the curative and adjuvant trials have generally been restricted to moderate radiation doses of 30 to 55 Gy.
In contrast to the curative or adjuvant setting, radiation has been effective in palliating RCC, especially in the metastatic setting.[11-13] Differences in results may be attributable to differences in radiation technique. Metastatic RCC has been treated with higher doses and more hypofractioned radiation including stereotactic radiosurgery, whereas curative cases have used lower total doses and conventional fractionations. RCC may be more responsive to radiation at higher doses or in a hypofractionated form (including stereotactic radiosurgery). Systemic treatments may also have synergistic effects with radiation.
Whole-brain radiation therapy (WBRT) has been the community standard for treating brain metastases from many types of cancers. In general, the median survival time for patients with brain metastases treated with steroids alone is about 2 months. WBRT can increase median survival by 1 to 4 months for most tumor types. The percentage of patients responding to WBRT varies greatly from study to study, with response rates of 50% to 70% generally reported. WBRT alone results in median survivals of 7.1, 4.2, and 2.3 months for Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) class I, II, and III, respectively, in patients with brain metastases from nonradioresistant tumors.
Despite the reports of radioresistance, retrospective studies suggest that WBRT is an effective treatment modality for patients with brain metastases from RCC. Patients with untreated brain metastases from RCC have a median survival of 3 to 4 months. In three retrospective series, patients with brain metastases from RCC treated with WBRT had slightly improved overall survivals of 3.0 to 7.0 months (Table 2).[17-19] Moreover, WBRT provided up to 60% local control (control at the sites of radiographically apparent disease), with only 8% of distant brain failure (incidence of new brain lesions away from initial sites of disease). Reports of median survivals according to RTOG RPA classes further support the effectiveness of WBRT for metastatic RCC (Table 3). The median survival in patients with brain metastases from RCC treated with WBRT is 8.5, 3, and 0.6 months for classes I, II, and III, respectively.
The role of dose escalation and/or hyperfractionation in WBRT for non-RCC brain metastases is controversial. The RTOG has conducted two randomized studies that demonstrated comparable results for different fractionation schedules—40 Gy in 15 or 20 fractions, 30 Gy in 10 or 15 fractions, and 20 Gy in 5 fractions.[20,21] In these randomized trials, there was no difference in neurologic function, duration of improvement, time to progression, or survival.
These results were recently challenged by Epstein and colleagues, who reported superior survival times and improved neurologic function in patients with solitary brain metastases using whole-brain doses of 32 Gy administered in 1.6 Gy fractions twice daily, followed by boost doses to 48, 54, 64, and 70 Gy. Survivals increased with increasing doses, from 4.9 months with 48 Gy to 8.2 months with 70 Gy. Nieder et al found that patients who received WBRT with 30 Gy in 10 fractions had half the response rate of the group receiving 40 to 60 Gy in 20 to 30 fractions but no survival benefits. These retrospective studies suggest that there may be a dose-response effect at higher doses, which is not evident at lower doses such as the ones used in the randomized RTOG trials.
Although there is some evidence that dose-escalation or hyperfractionation may improve response rates and survival in patients with non-RCC metastases, such data are scant in RCC. A retrospective study of RCC patients by Cannady and colleagues found that patients who receive more than 30 Gy had significantly longer survival than patients who received 30 Gy or less. This result, however, was confounded by the fact that patients who received higher doses also had better prognostic factors such as Karnofsky performance status and RPA class. Thus, it remains unclear whether a change in dose or fractionation has an impact on the treatment of RCC brain metastases.
WBRT continues to be the treatment of choice for patients with a single brain metastasis not amenable to surgery or radiosurgery, for patients with poorly controlled systemic disease and thus a relatively short life expectancy, and for patients with multiple brain metastases whose metastases are too numerous for stereotactic radiosurgery or surgery. The most commonly reported dose for WBRT in RCC is 30 Gy in 10 fractions. In practice, the dose and fraction size of WBRT should be individualized to take into consideration the status of systemic or extracranial disease as well as performance status. While higher fractional dose as well as total dose may increase the chance of complications, non-RCC research suggests that increased doses may improve quality of life and survival. Dose escalation in RCC should be explored especially in combination with other therapeutic modalities such as surgery, radiosurgery, and systemic therapy (eg, molecular targeted therapy).
The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article. Dr. Teh's work was supported by The Methodist Hospital Research Institute research grant.
1. Marshall FF, Stewart AK, Menck HR: The National Cancer Data Base: Report on kidney cancers. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 80:2167-2174, 1997.
2. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005.
3. Devesa SS, Silverman DT, McLaughlin JK, et al: Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control 1:133-141, 1990.
4. Flanigan RC, Campbell SC, Clark JI, et al: Metastatic renal cell carcinoma. Curr Treat Options Oncol 4:385-390, 2003.
5. Sheehan JP, Sun MH, Kondziolka D, et al: Radiosurgery in patients with renal cell carcinoma metastasis to the brain: Long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342-349, 2003.
6. Decker DA, Decker VL, Herskovic A, et al: Brain metastases in patients with renal cell carcinoma: prognosis and treatment. J Clin Oncol 2:169-173, 1984.
7. Delattre JY, Krol G, Thaler HT, et al: Distribution of brain metastases. Arch Neurol 45:741-744, 1988.
8. Wei K, Wandl E, Karcher KH: X-ray induced DNA double-strand breakage and rejoining in a radiosensitive human renal carcinoma cell line estimated by CHEF electrophoresis. Strahlenther Onkol 169:740-744, 1993.
9. Ning S, Trisler K, Wessels BW, et al: Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12 suppl):2519-2528, 1997.
10. Syljuasen RG, Belldegrun A, Tso CL, et al: Sensitization of renal carcinoma to radiation using alpha interferon (IFNA) gene transfection. Radiat Res 148:443-448, 1997.
11. Halperin EC, Harisiadis L: The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 51:614-617, 1983.
12. Wilson D, Hiller L, Gray L, et al: The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 15:400-407, 2003.
13. DiBiase SJ, Valicenti RK, Schultz D, et al: Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model. J Urol 158(3 pt 1):746-749, 1997.
14. Swift PS, Phillips T, Martz K, et al: CT characteristics of patients with brain metastases treated in RTOG study 79-16. Int J Radiat Oncol Biol Phys 25:209-214, 1993.
15. Kaye A, Laws E Jr (eds): Brain Tumors: An Encyclopedic Approach, 2nd ed.. New York, Churchill Livingstone, 2001.
16. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997.
17. Wronski M, Maor MH, Davis BJ, et al: External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37:753-759, 1997.
18. Cannady SB, Cavanaugh KA, Lee SY, et al: Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: A retrospective study. Int J Radiat Oncol Biol Phys 58:253-258, 2004.
19. Culine S, Bekradda M, Kramar A, et al: Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83:2548-2553, 1998.
20. Gelber RD, Larson M, Borgelt BB, et al: Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer 48:1749-1753, 1981.
21. Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1-9, 1980.
22. Epstein BE, Scott CB, Sause WT, et al: Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28. Cancer 71:1362-1367, 1993.
23. Nieder C, Berberich W, Nestle U, et al: Relation between local result and total dose of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 33:349-355, 1995.
24. Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990.
25. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583-590, 1993.
26. Mintz AH, Kestle J, Rathbone MP, et al: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470-1476, 1996.
27. Bindal RK, Sawaya R, Leavens ME, et al: Surgical treatment of multiple brain metastases. J Neurosurg 79:210-216, 1993.
28. Nussbaum ES, Djalilian HR, Cho KH, et al: Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78:1781-1788, 1996.
29. Wronski M, Arbit E, Russo P, et al: Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 47:187-193, 1996.
30. O’Dea M J, Zincke H, Utz DC, et al: The treatment of renal cell carcinoma with solitary metastasis. J Urol 120:540-542, 1978.
31. Salvati M, Scarpinati M, Orlando ER, et al: Single brain metastases from kidney tumors. Clinico-pathologic considerations on a series of 29 cases. Tumori 78:392-394, 1992.
32. Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280:1485-1489, 1998.
33. Lutz W, Winston KR, Maleki N: A system for stereotactic radiosurgery with a linear accelerator. Int J Radiat Oncol Biol Phys 14:373-381, 1988.
34. Yeung D, Palta J, Fontanesi J, et al: Systematic analysis of errors in target localization and treatment delivery in stereotactic radiosurgery (stereotactic radiosurgery). Int J Radiat Oncol Biol Phys 28:493-498, 1994.
35. Chang SD, Main W, Martin DP, et al: An analysis of the accuracy of the CyberKnife: a robotic frameless stereotactic radiosurgical system. Neurosurgery 52:140-147 (incl discussion), 2003.
36. Auchter RM, Lamond JP, Alexander E, et al: A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 35:27-35, 1996.
37. Muacevic A, Kreth FW, Horstmann GA, et al: Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg 91:35-43, 1999.
38. Soffietti R, Ruda R, Mutani R: Management of brain metastases. J Neurol 249:1357-1369, 2002.
39. Brown PD, Brown CA, Pollock BE, et al: Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery 51:656-667 (incl discussion), 2002.
40. Hoshi S, Jokura H, Nakamura H, et al: Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: Results in 42 patients. Int J Urol 9(11):618-627 (incl discussion), 2002.
41. Amendola BE, Wolf AL, Coy SR, et al: Brain metastases in renal cell carcinoma: management with gamma knife radiosurgery. Cancer J 6:372-376, 2000.
42. Wowra B, Siebels M, Muacevic A, et al: Repeated gamma knife surgery for multiple brain metastases from renal cell carcinoma. J Neurosurg 97:785-793, 2002.
43. Noel G, Valery CA, Boisserie G, et al: LINAC radiosurgery for brain metastasis of renal cell carcinoma. Urol Oncol 22:25-31, 2004.
44. Mori Y, Kondziolka D, Flickinger JC, et al: Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 83:344-353, 1998.
45. Schoggl A, Kitz K, Ertl A, et al: Gamma-knife radiosurgery for brain metastases of renal cell carcinoma: Results in 23 patients. Acta Neurochir (Wien) 140:549-555, 1998.
46. Goyal LK, Suh JH, Reddy CA, et al: The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 47:1007-1012, 2000.
47. Payne BR, Prasad D, Szeifert G, et al: Gamma surgery for intracranial metastases from renal cell carcinoma. J Neurosurg 92:760-765, 2000.
48. Hernandez L, Zamorano L, Sloan A, et al: Gamma knife radiosurgery for renal cell carcinoma brain metastases. J Neurosurg 97(5 suppl):489-493, 2002.
49. Fike JR, Cann CE, Turowski K, et al: Radiation dose response of normal brain. Int J Radiat Oncol Biol Phys 14:63-70, 1988.
50. Breneman JC, Warnick RE, Albright RE Jr, et al: Stereotactic radiosurgery for the treatment of brain metastases. Results of a single institution series. Cancer 79:551-557, 1997.
51. Shiau CY, Sneed PK, Shu HK, et al: Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys 37:375-383, 1997.
52. Alexander E 3rd, Moriarty TM, Davis RB, et al: Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87:34-40, 1995.
53. Flickinger JC, Kondziolka D, Lunsford LD, et al: A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 28:797-802, 1994.
54. Shirato H, Takamura A, Tomita M, et al: Stereotactic irradiation without whole-brain irradiation for single brain metastasis. Int J Radiat Oncol Biol Phys 37:385-391, 1997.
55. Shaw E, Scott C, Souhami L, et al: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291-298, 2000.
56. Suzuki S, Omagari J, Nishio S, et al: Gamma knife radiosurgery for simultaneous multiple metastatic brain tumors. J Neurosurg 93(suppl 3):30-31, 2000.
57. Serizawa T, Iuchi T, Ono J, et al: Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy. J Neurosurg 93(suppl 3):32-36, 2000.
58. Joseph J, Adler JR, Cox RS, et al: Linear accelerator-based stereotaxic radiosurgery for brain metastases: The influence of number of lesions on survival. J Clin Oncol 14:1085-1092, 1996.
59. Sanghavi SN, Miranpuri SS, Chappell R, et al: Radiosurgery for patients with brain metastases: A multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 51:426-434, 2001.
60. Kondziolka D, Patel A, Lunsford LD, et al: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427-434, 1999.
61. Chougule P, Burton-Williams M, Saris S: Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both. Int J Radiat Oncol Biol Phys 48(suppl):114, 2000.
62. Speruto P, Scott C, Andrews D: Stereotactic radiosurgery with whole brain radiation therapy improves survival in patients with brain metastases: Report of radiation therapy oncology group phase III study 95-08. Int J Radiat Oncol Biol Phys 54(suppl):3, 2002.
63. Sneed PK, Lamborn KR, Forstner JM, et al: Radiosurgery for brain metastases: Is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 43:549-558, 1999.
64. Ikushima H, Tokuuye K, Sumi M, et al: Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 48:1389-1393, 2000.
65. DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789-796, 1989.
66. Nieder C, Schwerdtfeger K, Steudel WI, et al: Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlenther Onkol 174:275-278, 1998.
67. Griffin T: White matter necrosis, microangiopathy and intellectual abilities in survivors of childhood leukemia. Association with central nervous system irradiation and methotrexate therapy., in Gilbert H, Kagan A (eds): Radiation Damage to the Nervous System. New York, Raven Press, 1980.
68. Giglio P, Gilbert MR: Cerebral radiation necrosis. Neurologist 9:180-188, 2003.
69. Kumar AJ, Leeds NE, Fuller GN, et al: Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377-384, 2000.
70. Sheline GE, Wara WM, Smith V: Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6:1215-1228, 1980.
71. Radcliffe J, Packer RJ, Atkins TE, et al: Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 32:551-554, 1992.
72. Cheung MC, Chan AS, Law SC, et al: Impact of radionecrosis on cognitive dysfunction in patients after radiotherapy for nasopharyngeal carcinoma. Cancer 97:2019-2026, 2003.
73. Cheung M, Chan AS, Law SC, et al: Cognitive function of patients with nasopharyngeal carcinoma with and without temporal lobe radionecrosis. Arch Neurol 57:1347-1352, 2000.
74. Komaki R, Meyers CA, Shin DM, et al: Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 33:179-182, 1995.
75. Laack N, Brown P, Furth A: Neurocognitive function after radiotherapy (RT) for supratentorial low-grade gliomas (LGG): results of a North Central Cancer Treatment Group (NCCTG) prospective study. Int J Radiat Oncol Biol Phys 57(2 suppl):S134, 2003.
76. Brown PD, Buckner JC, O’Fallon JR, et al: Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21:2519-2524, 2003.
77. Loeffler JS, Siddon RL, Wen PY, et al: Stereotactic radiosurgery of the brain using a standard linear accelerator: A study of early and late effects. Radiother Oncol 17:311-321, 1990.
78. Werner-Wasik M, Rudoler S, Preston PE, et al: Immediate side effects of stereotactic radiotherapy and radiosurgery. Int J Radiat Oncol Biol Phys 43:299-304, 1999.
79. Varlotto JM, Flickinger JC, Niranjan A, et al: Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57:452-464, 2003.
80. Urtasun RC, Band PR, Chapman JD, et al: Radiation plus metronidazole for glioblastoma. N Engl J Med 296:757, 1977.
81. Nelson DF, Schoenfeld D, Weinstein AS, et al: A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. Int J Radiat Oncol Biol Phys 9:1143-1151, 1983.
82. Nelson DF, Diener-West M, Weinstein AS, et al: A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys 12:1793-1800, 1986.
83. Overgaard J, Hansen HS, Overgaard M, et al: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 46:135-146, 1998.
84. Rischin D, Peters L, Hicks R, et al: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19:535-542, 2001.
85. Rischin D, Peters L, Fisher R, et al: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87, 2005.
86. Urtasun RC, Kinsella TJ, Farnan N, et al: Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, Phase I-II study. Int J Radiat Oncol Biol Phys 36:1163-1167, 1996.
87. Prados MD, Seiferheld W, Sandler HM, et al: Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147-1152, 2004.
88. Phillips TL, Scott CB, Leibel SA, et al: Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33:339-348, 1995.
89. Brada M, Ross G: Radiotherapy for primary and secondary brain tumors. Curr Opin Oncol 7:214-219, 1995.
90. Viala J, Vanel D, Meingan P, et al: Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases. Radiology 212:755-759, 1999.
91. Rosenthal DI, Nurenberg P, Becerra CR, et al: A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5:739-745, 1999.
92. Magda D, Lepp C, Gerasimchuk N, et al: Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 51:1025-1036, 2001.
93. Meyers CA, Smith JA, Bezjak A, et al: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22:157-165, 2004.
94. Greig N: Implications of the blood brain barrier and its manipulation, in Neuwelt E (ed): Brain Tumor and the Blood Tumor Barrier, vol 2. New York, Plenum, 1989.
95. Franciosi V, Cocconi G, Michiara M, et al: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 85:1599-1605, 1999.
96. Newlands ES, Blackledge GR, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291, 1992.
97. Stevens MF, Hickman JA, Langdon SP, et al: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852, 1987.
98. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002.
99. Gilbert MR, Friedman HS, Kuttesch JF, et al: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 4:261-267, 2002.
100. Christodoulou C, Bafaloukos D, Kosmidis P, et al: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12:249-254, 2001.
101. Abrey LE, Olson JD, Raizer JJ, et al: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53:259-265, 2001.
102. Friedman H, Evans B, Reardon D: Phase II trial of temozolomide for patients with progressive brain metastases (abstract 408). Proc Am Soc Clin Oncol 22:102, 2003.
103. Siena S, Landonio G, Baietta E: Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer (abstract 407). Proc Am Soc Clin Oncol 22:102, 2003.
104. Bafaloukos D, Gogas H, Georgoulias V, et al: Temozolomide in combination with docetaxel in patients with advanced melanoma: A phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 20:420-425, 2002.
105. Antonadou D, Paraskevaidis M, Sarris G, et al: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644-3650, 2002.
106. Antonadou D, Coliarakis N, Paraskevaidis M: Whole brain radiotherapy alone or in combination with temozolomide for brain metastasis. A phase III study. Int J Radiat Oncol Biol Phys 54:93-94, 2002.
107. Verger E, Gil M, Yay R: Concomitant temozolomide (TMZ) and radiotherapy (RT) in patients with brain metastasis: Randomized multicentric phase II study, a preliminary report (abstract 309). Proc Am Soc Clin Oncol 21:78a, 2002.
108. Verger E, Gil M, Yaya R: Concomitant temozolomide (TMZ) and whole brain radiotherapy (WBRT) in patients with brain metastasis (BM): Randomized multicentric phase II study (abstract 404). Proc Am Soc Clin Oncol 22:101, 2003.
109. Sunkara U, Walczak JR, Summerson L, et al: A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 24:37-41, 2004.
110. Park DK, Ryan CW, Dolan ME, et al: A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol 50:160-162, 2002.
111. Takahashi M, Rhodes DR, Furge KA, et al: Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci U S A 98:9754-9759, 2001.
112. Takahashi M, Sugimura J, Yang X, et al: Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Adv Cancer Res 89:157-181, 2003.
113. Tan MH, Rogers CG, Cooper JT, et al: Gene expression profiling of renal cell carcinoma. Clin Cancer Res 10:6315S-6321S, 2004.
114. Rogers CG, Tan MH, Teh BT: Gene expression profiling of renal cell carcinoma and clinical implications. Urology 65:231-237, 2005.